Improved foot-and-mouth disease vaccine with O PanAsia-2 strain protect pigs against O/Jincheon/SKR/2014 originated from South Korea. Issue 5 (29th January 2020) - Ko, Mi-Kyeong
Highlights: Type O, PanAsia-2-lineage vaccine strain, which belongs to the ME-SA topotype, was developed. The immunized pigs were all protected against O/Jincheon/SKR/2014 (SEA topotype). The immunized cattle had high titers of neutralizing antibodies in only two weeks. The antibody titer in immunized pigs was highest against the ME-SA topotype, followed by the SEA topotype. Immune responses to vaccine were relatively low against the EURO-SA and Cathay topotypes. Abstract: Efforts are required to develop foot-and-mouth disease (FMD) vaccines in Asia that can respond to the type O outbreaks that have continued with the devastating damage since 2010. It is necessary to develop vaccine strains that can provide protection against the ME-SA topotype, which has tended to spread into neighboring areas, and the frequent SEA topotype outbreaks. To this end, this study aimed to develop a FMD vaccine utilizing O PanAsia-2 that is able to provide broad protection against ME-SA as the vaccine strain, with a focus on the O/Jincheon/SKR/2014 virus (SEA topotype), the outbreaks of which have persisted in spite of the enforcement of FMD vaccination. The virus neutralizing antibody (VN) titer to the ME-SA topotype (especially, Ind2001 lineage) virus in pigs was the highest, followed by SEA, while the VN titers to the Cathay and EURO-SA topotypes were similar. In the O/Jincheon/SKR/2014 virus challenge test, all pigs were protected against the virus, and almost no virus shedding was detected after the virus challenge. In the immunization test performed on cattle and pigs, antibodies with sufficient protective activity were produced in cattle two weeks after the first immunization, and pigs exhibited lower immunity compared to cattle. However, immunity was improved enough in pigs to provide protection against the virus challenge after the second immunization, with a significant increase in antibody production.